The U.S. Food and Drug Administration (FDA) has granted INCB40093 Orphan Drug Designation (ODD) for the treatment of Hodgkin lymphoma (HL).  INCB4009 is a potent small molecule PI3Kδ inhibitor being developed by Incyte Inc., a biopharmaceutical company headquartered in Wilmington, DE.  PI3Kδ plays an essential role in promoting B-cell survival and excessive activation of PI3Kδ is associated with HL. HL is an uncommon lymphoma with a bimodal incidence curve.  Although HL has remained a largely curable disease, approximately 20% of patients will not be cured with currently available therapy and will require subsequent treatments.

 

Related Links:

http://www.streetinsider.com/Corporate+News/Incyte+%28INCY%29+Receives+Orphan+Drug+Designation+for+Treatment+of+Hodgkin+Lymphoma/10506476.html
http://www.google.com/patents/US8940752
http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=2042128
http://www.bloodjournal.org/content/bloodjournal/119/8/1897.full.pdf?sso-checked=true